NVIDIA and Lilly Launch $1B AI Lab for Drug Discovery
- NVIDIA and Eli Lilly will co-invest up to $1 billion over five years in an AI lab focused on developing biomedical foundation models.
- The lab, located in South San Francisco, aims to accelerate drug discovery by integrating wet and dry labs in a continuous AI learning loop.
- Utilizing NVIDIA BioNeMo, the initiative will enhance molecule identification and validation through large-scale data and compute resources.
- NVIDIA’s Vera Rubin architecture will be used alongside digital twins, robotics, and agentic AI to optimize pharmaceutical operations.
- Lilly’s TuneLab platform will incorporate NVIDIA Clara open foundation models for biotech partners, enhancing collaboration within the ecosystem.
The collaboration between NVIDIA and Eli Lilly seeks to revolutionize drug discovery by leveraging advanced AI technologies, with significant investment aimed at improving pharmaceutical research and development processes.
Source (3.2)https://cryptobriefing.com/nvidia-lilly-ai-lab/?rand=59535
